Sorafenib: new indication. For some patients with liver cancer.
In a trial involving patients with advanced-stage liver cancer but unimpaired hepatic function, sorafenib increased the median survival time by about 3 months in half of patients, but provoked frequent adverse effects.
D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009965:Orphan Drug Production; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects; D013534:Survival
D001557:Benzenesulfonates; D011725:Pyridines; D040262:Receptors, Vascular Endothelial Growth Factor